The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry.

Manasi AgrawalXian ZhangErica J BrennerRyan C UngaroMichael D KappelmanJean Frederic Colombel

Published in: Journal of Crohn's & colitis (2021)

COVID-19 outcomes among IBD patients on VDZ are comparable to those on all other therapies. Hospitalization, but not severe COVID-19, is more likely with VDZ monotherapy than with anti-TNF monotherapy. Overall, VDZ appears to be safe in IBD patients with COVID-19.

Keyphrases

coronavirus disease
sars cov
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
ulcerative colitis
rheumatoid arthritis
clinical trial
early onset
combination therapy
respiratory syndrome coronavirus